You searched for "Injection"
Oncological benefits of extended pelvic lymph node dissection
Touijer and colleagues present extended follow-up results from a large randomised trial comparing limited pelvic lymph node dissection (l-PLND) and extended PLND (e-PLND) in prostate cancer patients undergoing radical prostatectomy. The study aimed to assess whether e-PLND, which includes external...An update on mobile apps in urology
Amongst the plethora of mobile applications, there are some essential applications for practising urologists, urologists in training and patients. In this month’s digital review, we highlight some essential applications. Mobile office apps Maintaining a virtual office is key to keeping...Endoscopic management of upper tract urothelial carcinoma
Upper tract urothelial carcinoma (UTUC) is a rare disease accounting for 5-10% of all urothelial carcinomas and has an annual incidence in Western countries of 1-2 per 100,000 [1,2]. It occurs more commonly in the pelvicalyceal system as opposed to...Urological etymology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). I’ve always found the derivation of names fascinating. Anatomy lessons were made so...
Penn Clinical Manual of Urology: Third Edition
Traversing the spectrum of urology, this is the seventh iteration of this textbook, the third with Elsevier. It is clear from this edition that the team has been hard at work to update and fine-tune this resource. The preface of...Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...Prostate Scotland statement on National Screening Committee recommendation
Prostate Scotland notes the recommendation from the UK National Screening Committee (NSC) on Friday 28 November 2025 to introduce targeted prostate cancer screening only for men with confirmed BRCA1 or BRCA2 gene variants. While this represents an important first step...
